secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001193125-25-004091
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir shareholders approve reverse stock split ratio range 1:15–1:35; board to set exact ratio
--------------------------------------------------------------------------------

- 96,216,120 votes for, 12,082,172 against, 303,036 abstain; adjournment not needed.
- Reverse split ratio of any whole number between 1:15 and 1:35, effective before Jan 10, 2026.
- Board will determine exact ratio and timing without further shareholder approval.
- Split is in connection with proposed merger with Kalaris Therapeutics, Inc.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525004091/0001193125-25-004091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525004091/d899696d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-004091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer